Pulmonx Management
Management criteria checks 2/4
Pulmonx's CEO is Steve Williamson, appointed in Mar 2024, has a tenure of less than a year. directly owns 0.036% of the company’s shares, worth $87.60K. The average tenure of the management team and the board of directors is 2.9 years and 4.6 years respectively.
Key information
Steve Williamson
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.04% |
| Management average tenure | 2.9yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%
Oct 22
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?
Oct 02Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 15Pulmonx: Low Bar For Q2 Earnings
Jul 21Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch
Jun 07Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion
Apr 04Pulmonx: Revisiting Thesis Following Management Change
Mar 26Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?
Feb 23Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues
Aug 01Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically
Nov 08Pulmonx GAAP EPS of -$0.40 in-line, revenue of $14M beats by $0.23M
Aug 02Pulmonx: Interesting Technology But Struggling With Adoption
Jul 02These Analysts Just Made A Meaningful Downgrade To Their Pulmonx Corporation (NASDAQ:LUNG) EPS Forecasts
Feb 28CEO
Steve Williamson (51 yo)
less than a year
Tenure
Mr. Steven S. Williamson, also known as Steve, serves as CEO, President & Director of Pulmonx Corporation since March 15, 2024. He was Chief Commercial Officer of Outset Medical, Inc. since November 2020 u...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| General Counsel & Secretary | 4.2yrs | US$2.64m | 0.16% $ 389.1k | |
| Chief Commercial Officer | 4.9yrs | US$1.96m | 0.45% $ 1.1m | |
| CEO, President & Director | less than a year | no data | 0.036% $ 87.6k | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Technical Officer | 4.9yrs | no data | no data | |
| Vice President of Marketing | no data | no data | no data | |
| Vice President of Sales (U.S.) | 2.8yrs | no data | no data | |
| Chief People Officer | 2.9yrs | no data | no data | |
| Senior VP & GM of Europe Middle-East & Africa | no data | no data | no data | |
| VP & Corporate Controller | less than a year | no data | 0.049% $ 120.2k |
2.9yrs
Average Tenure
54yo
Average Age
Experienced Management: LUNG's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | no data | 0.036% $ 87.6k | |
| Independent Chairperson of the Board | 14.8yrs | US$228.21k | 0.13% $ 316.2k | |
| Independent Director | 17.8yrs | US$213.21k | 0.11% $ 262.3k | |
| Director | 10yrs | US$5.80m | 2.31% $ 5.6m | |
| Independent Director | 4.3yrs | US$213.21k | 0.12% $ 291.2k | |
| Independent Director | 4.3yrs | US$200.71k | 0.053% $ 129.3k | |
| Independent Director | 4.9yrs | US$220.71k | 0.11% $ 255.5k | |
| Independent Director | 3.4yrs | US$198.21k | 0.054% $ 130.9k |
4.6yrs
Average Tenure
62.5yo
Average Age
Experienced Board: LUNG's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:41 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pulmonx Corporation is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |